BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/29/2026 7:26:46 AM | Browse: 4 | Download: 28
 |
Received |
|
2025-10-27 11:54 |
|
Peer-Review Started |
|
2025-10-27 11:54 |
|
First Decision by Editorial Office Director |
|
2025-11-14 09:24 |
|
Return for Revision |
|
2025-11-14 09:24 |
|
Revised |
|
2025-12-22 12:09 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-02-10 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-10 11:19 |
|
Articles in Press |
|
2026-02-10 11:19 |
|
Edit the Manuscript by Language Editor |
|
2026-02-15 22:37 |
|
Typeset the Manuscript |
|
2026-04-22 07:06 |
|
Publish the Manuscript Online |
|
2026-05-29 07:26 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Strategic integration of immunotherapy with chemotherapy, radiotherapy, and targeted therapy in gastric cancer management: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yashwant Kumar Ratre, Nilabh Ghritlahre, Babita Pande, Tarun Sahu, Lakkakula Suhasini Sahithi, Shashikant Swarnkar and Henu Kumar Verma |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Henu Kumar Verma, Assistant Professor, Department of Bioscience and Biomedical Engineering, Indian Institute of Technology, Kutelabhata, Bhilai 491002, Chhattisgarh, India. henu.verma@yahoo.com |
| Key Words |
Gastric cancer; Immunotherapy; Chemotherapy; Radiotherapy; Targeted therapy; Management |
| Core Tip |
Gastric cancer remains challenging to treat due to late diagnosis and limited response to standard therapies. Immunotherapy, especially programmed cell death 1/programmed cell death ligand 1 inhibitors like pembrolizumab and nivolumab, has shown promising results in improving survival. This systematic review emphasizes the benefits of integrating immunotherapy with chemotherapy, radiotherapy, and targeted therapy to enhance antitumor efficacy through mechanisms such as immunogenic cell death and the abscopal effect. Future studies should focus on optimizing treatment sequencing, dosing, and biomarker-based patient selection to refine combination strategies and improve survival and quality of life in gastric cancer patients. |
| Publish Date |
2026-05-29 07:26 |
| Citation |
Ratre YK, Ghritlahre N, Pande B, Sahu T, Sahithi LS, Swarnkar S, Verma HK. Strategic integration of immunotherapy with chemotherapy, radiotherapy, and targeted therapy in gastric cancer management: A systematic review. World J Gastroenterol 2026; 32(22): 115807 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i22/115807.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i22.115807 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
